XB596, a promising bis-naphthalimide anti-cancer agent

Anti-Cancer Drugs

Volumn 4, Issue 4, 1993, Pages 447-457

  Chen, S F ^a   Behrens, D L ^a   Behrens, C H ^a   Czerniak, P M ^a   Dexter, D L ^a   Dusak, B L ^a   Fredericks, J F ^a   Gale, K C ^a   Gross, J L ^a   Jiang, J B ^a   Kirshenbaum, M R ^a   McRipley, R J ^a   Papp, L M ^a   Patten, A D ^a   Perrella, F W ^a   Seitz, S P ^a   Stafford, M P ^a   Sun, J H ^a   Wuonola, M A ^a  

^a Alpha Center ^*  (United States)

Author keywords

Anti tumor agents; Bis naphthalimide compounds; DNA; XB596

Indexed keywords

4 [3 (3 NITRONAPHTHALENE 1,8 DICARBOXIMIDO)PROPYLAMINO] 1 (3 NITRONAPHTHALENE 1,8 DICARBOXIMIDO)BUTANE; AMONAFIDE; ANTINEOPLASTIC AGENT; DNA; DOXORUBICIN; INTERCALATING AGENT; MITOXANTRONE; NAPHTHALIMIDE DERIVATIVE; RADIOISOTOPE; RNA; UNCLASSIFIED DRUG; XB 596;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INTERCALATION COMPLEX; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LEUKEMIA L 1210; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEIC ACID SYNTHESIS; SOLID TUMOR;

EID: 0027234007     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199308000-00005     Document Type: Article

References (0)